) [153]. This method is at present not scalable since it relies on expensive startup substrates which may be used to produce psilocybin in more affordable chemical synthesis methodologies. A methodology for de novo manufacture of psilocybin and tryptamine derivatives in Saccharomyces cerevisiae, added limitations to psilocybin pharmaceutical study